SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
NEW YORK, Aug. 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Sinovac Biotech Ltd. ("Sinovac Biotech Ltd.") (NASDAQ:SVA) between April 30, 2013 and May 16, 2017. You are hereby notified that a securities class action lawsuit has been commenced in District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-sba/sinovac-biotech-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Defendant Weidong Yin, Sinovac’s Chairman and CEO, bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; (2) Yin's conduct would subject Sinovac to heightened regulatory scrutiny; and (3) subsequently, Sinovac’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Sinovac Biotech Ltd. you have until September 1, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
